Literature DB >> 35358293

Expression of Concern: Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome Formation.

.   

Abstract

Entities:  

Year:  2022        PMID: 35358293      PMCID: PMC8970492          DOI: 10.1371/journal.pone.0266498

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


× No keyword cloud information.
After this article [1] was published, concerns were raised about similarities in some of the microscopy images in Figures 1A and 1D. Specifically: In Figure 1A in this article, the 0 RBV (μg/ml), 100 IFN-α (IU/ml) panel appears similar to the 40 RBV (μg/ml), 10 IFN-α (IU/ml) panel; the 10 RBV (μg/ml), 0 IFN-α (IU/ml) panel appears similar to the 20 RBV (μg/ml), 10 IFN-α (IU/ml) panel; and the 20 RBV (μg/ml), 0 IFN-α (IU/ml) panel appears similar to the 20 RBV (μg/ml), 1000 IFN-α (IU/ml) panel. In Figure 1D in this article, the 0 RBV (μg/ml), 100 IFN-α (IU/ml) panel appears similar to the 10 RBV (μg/ml), 10 IFN-α (IU/ml) panel; and the 0 RBV (μg/ml), 250 IFN-α (IU/ml) appears similar to the 20 RBV (μg/ml), 250 IFN-α (IU/ml) panel. Follow-up on these issues is ongoing; in the meantime, the PLOS ONE Editors issue this Expression of Concern. In addition, please note that reference 16 in this article [1] has been retracted [2].
  2 in total

1.  Alpha interferon inhibits translation mediated by the internal ribosome entry site of six different hepatitis C virus genotypes.

Authors:  Sidhartha Hazari; Asha Patil; Virendra Joshi; Deborah E Sullivan; Cesar D Fermin; Robert F Garry; Richard M Elliott; Srikanta Dash
Journal:  J Gen Virol       Date:  2005-11       Impact factor: 3.891

2.  Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation.

Authors:  Rajesh Panigrahi; Sidhartha Hazari; Sruti Chandra; Partha K Chandra; Sibnarayan Datta; Ramazan Kurt; Craig E Cameron; Zhuhui Huang; Haitao Zhang; Robert F Garry; Luis A Balart; Srikanta Dash
Journal:  PLoS One       Date:  2013-08-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.